Abstract 32P
Background
International guidelines recommend a combination of NK1, 5-HT3 receptor antagonists, and dexamethasone (DEX) as standard antiemetic therapy for patients treated with a doxorubicin and cyclophosphamide (AC) regimen. However, DEX has been associated with several side effects, including diabetes, osteoporosis, and immunosuppression. Additionally, pneumocystis pneumonia, a rare but fatal condition, has been reported, predominantly in patients undergoing the dose-dense AC (ddAC) regimen.
Methods
We recruited 30 patients with Stage I-III breast cancer who received the ddAC regimen. Patients were administered prophylactic olanzapine (OLZ) 5 mg/day on days 1 to 4 in addition to the standard three-drug combination antiemetic regimen, with DEX omitted on days 2 and 3. Nausea/vomiting and drowsiness were evaluated using a 4-point Likert scale questionnaire previously employed in the J-FORCE study, which assessed the efficacy of OLZ 5 mg in high-emetic-risk regimens. The primary endpoint was complete response (CR) rate in the delayed phase (24-120 hours post chemotherapy administration) of the first cycle. Secondary endpoints included the total control (TC) rate of nausea and vomiting, complete control (CC) rate, degree of daytime sleepiness, and quality of life as assessed by EORTC QLQ-C30 Ver.3.
Results
Among the participants, 22 patients (73%) received ddAC as neoadjuvant chemotherapy and 8 (27%) as adjuvant chemotherapy. Median age at the start of treatment was 56 years. CR rates were 73% and 63% in the acute and delayed periods, respectively. TC and CC rates in the acute period were 60% and 73%, whereas those in the delayed period were 36.6% and 63%, respectively. In both periods, 40% of patients experienced moderate or severe sleepiness. Mean scale scores for nausea on the EORTC QLQ-C30 remained within the Minimally Important Difference score level throughout the 4th cycles of treatment.
Conclusions
This prospective pilot study suggests that the addition of OLZ 5mg allows the omission of steroids without a worsening of CINV in patients with ddAC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract